# Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

> **NCT03191149** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (estimated)

## Conditions studied

- Advanced Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography with Contrast
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03191149
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-25
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03191149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03191149, "Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03191149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*